首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1767679

Herceptin市场按类型、应用、分销管道、付款人类型、给药途径、治疗线、患者属性和地区划分

Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography

出版日期: 2025年06月12日 | 出版商:

Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录

Herceptin市场规模预计在 2025 年为 33 亿美元，预计到 2032 年将达到 48.4 亿美元，2025 年至 2032 年的复合年增长率为 5.62%。

分析范围		分析详细信息
基准年	2024	市场规模（2025年）	33亿美元
效能数据	2020-2024	预测期	2025-2032
预测期内的复合年增长率（2025-2032）	5.62%	预计金额（2032年）	48.4亿美元

近年来，受 HER2 阳性乳癌发病率上升及标靶治疗需求成长的推动，全球Herceptin市场经历了显着成长。Herceptin，又称曲妥珠单抗，是一种特异性针对 HER2 蛋白的单株抗体，该蛋白在约 20-30% 的乳癌中过度表现。

该药物彻底改变了 HER2 阳性乳癌的治疗模式，改善了患者的预后和存活率。Herceptin的适应症不断扩大，包括其用于治疗 HER2 阳性转移性胃癌，进一步推动了市场的成长。此外，生物相似药的开发以及Herceptin与其他治疗方法联合使用的日益普及，为市场成长开闢了新的途径。本报告对全球Herceptin市场进行了详细分析，重点介绍了市场驱动因素、限制因素、机会和未来前景。

市场动态：

全球Herceptin市场受到多种因素驱动，包括 HER2 阳性乳癌发病率的上升、标靶治疗意识的增强以及个人化医疗需求的不断增长。 HER2 表达伴随诊断测试的发展也促进了市场成长，因为它能够识别出最能从Herceptin治疗中受益的患者。然而，Herceptin治疗的高成本可能会限制其在某些地区的普及，从而抑制市场成长。此外，生物相似药的出现和Herceptin在某些国家的专利到期到期也可能影响原厂药的市场占有率。儘管有这些挑战，市场提供了巨大的成长机会，包括Herceptin适应症扩展到其他 HER2 阳性癌症、开发新型药物组合以及Herceptin在新兴经济体中的日益普及。此外，旨在提高Herceptin疗效和安全性的持续研发预计将在未来推动市场成长。

本报告的主要特点

本报告对全球Herceptin市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。
它还强调了每个细分市场的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
全球Herceptin市场的主要企业是根据公司概况、产品系列、主要亮点、财务绩效和策略等参数进行分析的。
透过本报告的见解，负责人和企业经营团队可以就未来的产品发布、合作伙伴关係、市场扩张和行销策略做出明智的决策。
「全球Herceptin市场」报告涉及该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球Herceptin市场的各种策略矩阵来促进他们的决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 3.30 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.62%	2032 Value Projection:	USD 4.84 Bn

The global Herceptin market has witnessed significant growth in recent years, driven by the increasing prevalence of HER2-positive breast cancer and the rising demand for targeted therapies. Herceptin, also known as trastuzumab, is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed in approximately 20-30% of breast cancers.

The drug has revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and survival rates. The market's growth is further fueled by the expanding indications of Herceptin, including its use in the treatment of HER2-positive metastatic gastric cancer. Moreover, the development of biosimilars and the increasing adoption of Herceptin in combination with other therapies have opened up new avenues for market growth. This report provides an in-depth analysis of the global Herceptin market, highlighting its key drivers, restraints, opportunities, and future prospects.

Market Dynamics:

The global Herceptin market is driven by several factors, including the rising incidence of HER2-positive breast cancer, increasing awareness about targeted therapies, and the growing demand for personalized medicine. The development of companion diagnostic tests for HER2 expression has also contributed to the market's growth by enabling the identification of patients who are most likely to benefit from Herceptin treatment. However, the market growth is restrained by the high cost of Herceptin therapy, which may limit its accessibility in certain regions. Additionally, the emergence of biosimilars and the expiration of patents for Herceptin in some countries may impact the market share of the original drug. Despite these challenges, the market presents significant opportunities for growth, such as the expanding indications of Herceptin in other HER2-positive cancers, the development of novel drug combinations, and the increasing adoption of Herceptin in emerging economies. Furthermore, the ongoing research and development activities aimed at improving the efficacy and safety of Herceptin are expected to drive market growth in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global Herceptin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Herceptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech (Roche), Amgen, Pfizer, Merck & Co., AbbVie, Celgene, Bristol-Myers Squibb, AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, and EMD Serono
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Herceptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Herceptin market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Biologic
- Biosimilars
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Breast Cancer Treatment
- Gastric Cancer Treatment
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Payer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
Administration Route Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Subcutaneous
Treatment Line Insights (Revenue, USD Bn, 2020 - 2032)
- First-line Treatment
- Second-line Treatment
- Third-line Treatment
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Pediatric
- Adult
- Geriatric
- Gender
- Male
- Female
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Genentech (Roche)
- Amgen
- Pfizer
- Merck & Co.
- AbbVie
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- GSK (GlaxoSmithKline)
- Novartis
- Sanofi
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- EMD Serono

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Herceptin Market, By Type
- Global Herceptin Market, By Application
- Global Herceptin Market, By Distribution Channel
- Global Herceptin Market, By Payer Type
- Global Herceptin Market, By Administration Route
- Global Herceptin Market, By Treatment Line
- Global Herceptin Market, By Patient Demographics
- Global Herceptin Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Herceptin Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biologic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Herceptin Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Breast Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gastric Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Herceptin Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Herceptin Market, By Payer Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Herceptin Market, By Administration Route, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Herceptin Market, By Treatment Line, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
First-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Second-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Third-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Herceptin Market, By Patient Demographics, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Pediatric
  - Adult
  - Geriatric
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Male
  - Female

11. Global Herceptin Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

12. Competitive Landscape

Genentech (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
EMD Serono
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

13. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

14. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Herceptin市场按类型、应用、分销管道、付款人类型、给药途径、治疗线、患者属性和地区划分